One of the most consistently deleted chromosomal regions in solid tumours is 11q23 ± q25, which consequently has been postulated to harbour one or more tumour suppressor loci. Despite large eorts to identify the responsible genes, the goal remains elusive, but as knowledge accumulates new candidates are emerging. The present study was undertaken in an attempt to assess the possible implication of four genes residing at 11q23 ± q24, in a population of early onset breast cancer (n=41). The coding sequence of PIG8, CHK1, LOH11CR2A and PPP2R1B were screened for mutations using the protein truncation test or single-strand conformational polymorphism, in combination with direct DNA sequencing. Varying proportions of alterations were detected, ranging from 6% in PPP2R1B to 39% in PIG8. Many of these changes were deletions, in some cases corresponding to complete exons, thus likely to represent splice variants, while others were presumed to arise from aberrant splicing, since they occurred at sites with resemblance to exon/intron borders. Considering only bona ®de mutations, the highest alteration frequency (17%) was again found in PIG8. Most of these alterations were likely to have an adverse impact on the translated protein as they either altered the reading frame or aected phylogenetically conserved residues. Our data represent the ®rst evidence of alterations in the PIG8 gene in human malignancies, a ®nding that substantiates its role as a potential tumour suppressor gene as suggested by its involvement in p53-induced apoptosis. Oncogene (2001) 20, 7753 ± 7760.
Introduction
In spite of the increasing number of reports suggesting the 11q23 ± q25 region as likely to harbour one or more tumour suppressor genes, the inactivation of which could be implicated in a number of solid tumours Herbst et al., 1999; Hui et al., 1996; Kerangueven et al., 1997; Murakami et al., 1998) , their de®nitive identi®cation remains elusive. In breast cancer, the characterization of the ATM gene (Savitsky et al., 1995a,b) promised to mark the end of the search for candidates, as early studies indicated an increased breast cancer risk in relatives of Ataxia Telangiectasia (AT) patients (Easton, 1994; Swift et al., 1991) . Later studies performed on European populations of relatives to AT patients, demonstrated that the highest increase in risk were found in subjects below 45 ± 55 years of age (Janin et al., 1999; Olsen et al., 2001) , while contrary results were reported in an American study (Athma et al., 1996) . A considerable number of studies have been conducted to evaluate the involvement of ATM in sporadic breast cancer by looking for mutations, but reports have been inconsistent (Bebb et al., 1999; Broeks et al., 2000; FitzGerald et al., 1997; Izatt et al., 1999a,b; Vorechovsky et al., 1996) . Furthermore, Laake et al. (2000) demonstrated that truncating ATM mutations are not signi®cantly associated with LOH of the corresponding locus, suggesting that the 30 ± 50% range of allelic loss in this region might result from inactivation of other genes.
Recently, several new candidates have emerged. Due to its signi®cant role in DNA repair mechanisms, a lot of interest has been focused on the checkpoint kinase CHK1, which arrests cells with acquired DNA damages in late G2-phase, thereby preventing the segregation of chromosomal aberrations to the daughter cells (Sanchez et al., 1997) . So far, mutations have only been reported in a subset of colorectal and endometrial cancers, classi®ed as genetically unstable by virtue of microsatellite instability (Bertoni et al., 1999) . Also the PPP2R1B gene, coding for the beta subunit of the protein phosphatase PP2A believed to be involved in various cell cycle controlling pathways (Walter and Mumby, 1993; Wera and Hemmings, 1995) , have caught researchers attention. Up to date, mutations have been found at low frequency in lung, colon and breast cancer (Calin et al., 2000; Takagi et al., 2000; Wang et al., 1998) . A third candidate gene, named PIG8, is the human homologue of murine EI24, the expression of which was found to be induced by p53 overexpression in NIH3T3 cells that had been treated with the cytotoxic drug etopoxide Lehar et al., 1996) . In an attempt to identify downstream targets of p53, Polyak and colleagues used p53 null cell lines, which undergo apoptosis in response to exogenous p53 expression, to study the expression pattern of 7202 mRNA transcripts upon Adenoviral p53-induction (Polyak et al., 1997) . Employing serial analysis of gene expression (SAGE) they found that transcription was induced for 14 dierent mRNA's, of which 13 were not previously known to be p53 targets in human cells. These p53 inducible genes (PIG's) were given numbers 1 ± 13, of which number 8 was found to be homologous to murine EI24. The localization of the PIG8 gene was just recently mapped by the group of Gu et al. (2000a) to chromosome 11q23 ± q24. There are indications that PIG8 could act as a downstream mediator of p53-dependent apoptosis (Polyak et al., 1997; Gu et al., 2000b) , supporting the notion of PIG8 as a tumour suppressor. In 1997, Monaco et al. (1997) cloned a gene at 11q22 ± q24 in search of the target for LOH in lung, ovarian and breast carcinomas. The structure of the whole gene, named LOH11CR2A (also denoted BCSC-1), was elucidated and both cell lines and patients with the above mentioned malignancies were screened for mutations. Their data did not, however, present any compelling evidence for involvement of this gene in the tumourigenic process of lung, breast or ovarian tumours. The ®ndings of Monaco et al. (1997) are yet to be con®rmed or contradicted by others.
In previous investigations we have con®rmed that LOH at 11q23 ± q25 also occurs frequently in consecutive breast cancer cases with early onset (Gentile et al., 1999b) . Interestingly, our data also showed that LOH of the more telomeric part of this region correlates with higher tumour malignancy grade and reduced survival (Gentile et al., 2001) , possibly suggesting that inactivation of a gene at the telomere of 11q might promote a more aggressive tumour phenotype. The present study was carried out in an attempt to identify one or more target genes in this area. Thus, 41 breast cancer cases with early onset (443 years at diagnosis) were screened for truncating mutations at the mRNA level using the Protein Truncation Test (PTT)/direct DNA sequencing in CHK1, PPP2R1B and LOH11CR2A. In addition, we also assessed the extent of mutations in PIG8 using single-strand conformational polymorphism (SSCP)/ direct DNA sequencing on mRNA.
Results
We screened the coding regions of four genes, whose localization and predicted or known function qualify them as tumour suppressor candidates in early onset breast cancer, for mutations using PTT or SSCP in combination with direct DNA sequencing in 41 tumour specimens. Successful analysis was achieved in 34, 36, 38 and 41 of the cases in LOH11CR2A, PPP2R1B, CHK1 and PIG8, respectively. Table 1 summarizes the ®ndings made in the four genes, including frequency, location and nature of the alteration in the coding sequence as well as the predicted consequence for the translated protein. In total, alterations in any of the four mRNA analysed were found in 59% of the cases, the most frequently altered being PIG8. In some cases, DNA sequencing failed to identify any alteration although PTT or SSCP had demonstrated a mobility shift. This was in part attributable to heterozygous deletions leading to superimposed DNA sequences impossible to resolve from one another, and in part probably a consequence of complex multiple deletions, at times combined with insertions, dicult to interpret unambiguously.
PIG8
The coding portion of PIG8 was screened through SSCPanalysis. Band shifts were detected in 19 subjects, ®ve of which showed altered mobility in more than one part of the sequence. DNA sequencing con®rmed alterations in 16 cases bringing the total alteration frequency to 39%. Four dierent deletions were observed in more than one sample, three of these caused a shift in the reading frame and introduction of premature termination signals in the amino acid sequence at codons 106, 278 and 337, and one that retained the original reading frame and lacked codons 147 ± 187. The most frequently occurring deletion was found in ®ve (12%) out of the 41 samples. Three additional deletions, one frameshift, one retaining the correct reading frame and one that eliminated the initiation of translation signal, were found in single cases. In total, seven dierent single-base substitutions were observed, six of the missense type and one that was silent. Missense mutations at codons 195 ± 197 were found in the same specimen (#16), which in addition also carried the change at codon 30 and three further alerations.
CHK1
PTT analysis of the complete coding sequence identi®ed six samples with mobility shifts, ®ve of which (13% of informative cases) were con®rmed by direct sequencing. Three of the cases had deletions of exon 3, with no signs of splice site mutations in the corresponding DNA. The deletion alters the reading frame of the remaining sequence and introduces a stop codon terminating the sequence after only 118 amino acids, compared to the 476 residues of the full-length product. The remaining two cases shared an identical deletion of 135 bases between positions 773 ± 907, spanning portions of exons 7 and 8, but keeping the original reading frame.
LOH11CR2A
The 10 exons comprising the coding sequence were screened for mutations using PTT. Band shifts were observed in 13 cases. Direct sequencing identi®ed alterations in seven (21% of informative cases) of the samples, which all shared the same deletion. It was found that 715 bases were missing in the 5' portion of the mRNA, comprising exons 2 ± 6. The deletion causes a shift in the reading frame and it also creates a premature stop after 96 amino acids, thus resulting in a protein with only the ®rst exon in common with the full-length product. In addition, three of the samples carrying the deletion were also found to harbour dierent nucleotide substitutions at positions 71, 93 and 104 of the coding sequence, all leading to amino acid changes.
PPP2R1B
Eight samples were found to exhibit mobility shifts when the coding sequence comprising 15 exons was analysed using PTT, although only two (6% of informative cases) of these could be con®rmed. DNA sequencing identi®ed two extensive deletions of 600 and 752 bases, positioned between 1065 ± 1664 and 60 ± 811 of the coding region, the latter being of the frame shift type and inserting a stop codon predicted to result in a translated product of 25 amino acids.
Discussion
In the chase for novel tumour suppressor genes, LOH studies have been of invaluable importance in identifying regions of interest in the genome. One such region, shown to be implicated in many types of solid tumours is chromosome 11q23 ± q25 Herbst et al., 1999; Hui et al., 1996; Kerangueven et al., 1997; Murakami et al., 1998) . In breast cancer, allelic imbalance has been reported to range in magnitude between 30 ± 50% (Hampton et al., 1994; Kerangueven et al., 1997; Koreth et al., 1997; Negrini et al., 1995) , a ®gure that was previously con®rmed by our group to be valid also in a population of early onset cases (Gentile et al., 1999b; . We, and others, further found that loss of chromosomal material at several dierent loci in this region confers a more adverse prognosis and a more malignant phenotype (Laake et al., 1999; Gentile et al., 2001 ). The present study was carried out with the intent to assess the involvement of four candidate genes in breast cancer aecting young women. Our data demonstrated that alterations were present in all genes, the highest proportion being detected in PIG8, a highly signi®cant ®nding as this is the ®rst report showing that this gene, proposed to act as a mediator of p53-dependent apoptosis (Polyak et al., 1997; Gu et al., 2000b) , is indeed a mutational target in human cancer.
Almost exclusively, the type of alterations found in the present study were deletions, which is to be expected as PTT analysis cannot detect mutations that do not lead to premature termination of the translation product. However, to a large extent this was also the case for the PIG8 gene, which was screened using SSCP, a technique capable of detecting most types of mutations (reviewed by Hayashi and Yandell, 1993) . The position of the stop codon in the amino acid sequence was calculated taking the deleted codons into account Furthermore, many of the deletions were found in multiple cases, one of them occurring in as many as seven out of 34 cases. The alterations seem to vary largely in size and do not appear to focus around any particular region of the coding sequences, but when looked upon in detail a pattern starts to emerge. Most of the deletions either aect one or more exons or they occur at sites which bear a striking resemblance to exon/intron borders, i.e. directly adjacent to the canonical AG sequence. The reason for these aberrantly spliced mRNA's is not clear. For the samples exhibiting skipping of exon 3 in the mRNA of CHK1, we analysed the gene sequence for alterations in the intron/exon boundaries, but failed to identify such mutations. We did however ®nd single nucleotide substitutions in all three samples inside intron 2 (data not shown). Possibly, these alterations could interfere with the structural con®guration of the mRNA, thereby aecting the eciency of the correct donor/ acceptor sites and perhaps enhancing the eciency of others, thus resulting in an abundance of aberrantly spliced mRNA's. Similar observations have been reported previously in the Fibrillin-1 gene (Liu et al., 1997) , where a silent mutation was found to cause skipping of an exon. Moreover, the signi®cance of alterations in splice enhancers located in intronic sequences close to the exon border, have been demonstrated by Valentine (1998) , who found that exon skipping was frequently the result of this kind of alterations. As we did not have access to a population of healthy controls, we do not know at this point whether these aberrations are tumour-associated or if they occur at similar frequencies also in normal tissue. Until this point has been addressed, we need to interpret this type of alteration with caution and not consider them as bona ®de mutations.
Taking into account only alterations not classi®able in the above mentioned category, puts a dierent perspective on our data. No alterations are then left in CHK1 and only the three point mutations should be considered in LOH11CR2A. PPP2R1B would still have two cases with extensive deletions. Four of the deletions found in PIG8 should be disregarded, leaving the total number of altered cases at a still relatively high level of seven out of 41 (17%) cases, suggesting the PIG8 gene as the most signi®cant of the four. In fact, the extent of involvement of PIG8 is on a par with our previous ®ndings in a similar patient population in which we assessed the mutation frequency of the p53 gene (Gentile et al., 1999a) , an indication of how signi®cant this ®nding could be. It should be stressed though, that direct comparison between data attained by SSCP and PTT should be carried out cautiously as the detection capabilities of the two screening methods are not identical and results may therefore exhibit some degree of discordance.
As there are no previous mutation studies made on PIG8, and as the crystal structure of the protein is still not elucidated, the interpretation of their consequences for the resulting protein product must remain tentative. Naturally, the frameshift deletion leading to a predicted transcript of only 137 amino acids (aa), the fulllength protein being 340 aa, as well as the one aecting the initiation of translation, are likely to abrogate the function of the protein. The eect of the deletion of aa's 15 ± 28 is more dicult to predict and the same is true for the dierent point mutations, as it is not evident whether these changes may aect the structure of the protein. Clues to the likely eects of speci®c alterations on structural and functional domains of a protein can be obtained by searching databases for similarity with previously characterized motifs in known proteins. Gu et al. (2000b) performed such a search but failed to identify any obvious structural or functional motifs, except that PIG8 contains six putative membrane spanning domains, hinting as to its cellular localization, but giving away nothing as to its function. A second approach is to look for evolutionary conserved regions in the amino acid sequence. Performing multiple sequence alignment between the amino acid sequences of human, mouse, drosophila melanogaster and c. elegans we found a large portion of the amino acid sequence to be phylogenetically conserved (data not shown). More speci®cally, residues 195, 196 and 199 are highly conserved in all four species, suggesting that substitutions of these might have an adverse eect on the structure of the protein, possibly also aecting its function. Given the role of PIG8 as a mediator of p53-dependend apoptosis (Gu et al., 2000b; Polyak et al., 1997) , inactivating alterations could impair the apoptotic machinery. In combination with defects in the DNA damage repair mechanisms, this could result in cells with accumulating gene alterations not being targeted for programmed cell death, possibly leading to cellular transformation.
The two deletions observed in the mRNA of PPP2R1B, were either so large, shifted the reading frame or both, that proper function of the protein was most likely aected. There are several studies investigating alterations in PPP2R1B in dierent types of cancer including, cancer of the breast, colon, cervix, ovarian and lung (Calin et al., 2000; Takagi et al., 2000; Wang et al., 1998) . Alterations have been reported in all but ovarian cancers at frequencies consistent with the 6% found in the present study. Most of these alterations have been nucleotide substitutions leading to amino acid changes, but deletions in the mRNA have also been reported (Calin et al., 2000; Wang et al., 1998) , although none of these were as extensive as those found in the present study. The crystal structure of the protein is yet to be published but it is known from interaction studies that parts of the protein participates in binding to the b regulatory subunit of PP2A (Mumby and Walter, 1993) . Both the deletions found in our study and the exclusion of exon 9 reported by Calin et al. (2000) , aects the site of interaction between the regulatory and structural subunits, presumably abrogating the proper function of the holoenzyme.
Since Monaco et al. (1997) ®rst cloned the LOH11CR2A gene and analysed it for mutations, there have been no other studies published covering alterations or other aspects of the gene. Our data demonstrate a moderate percentage of alterations (9%), all of which were missense mutations. In the report of Monaco, lung, ovarian and breast carcinomas were screened for mutations using SSCP/direct sequencing in 132, 40 and 80 tumour specimens, respectively. They reported a total of four dierent nucleotide changes leading to amino acid substitutions. However, most of them were believed to be polymorphisms as they occurred in many cases and in all three tumour types. In fact, only one amino acid substitution occurred in a single case of one tumour type, but the alteration was detected also in the matched normal tissue of the breast cancer patient, excluding the event of a bona ®de somatic mutation. Based on the near absence of alterations, and the lack of evidence of any functional/biological consequence thereof, they concluded that the gene was not likely to be a mutational target in the tumourigenic process of breast, lung or ovarian cancers. Our data may suggest otherwise, especially when keeping in mind that the detection of the three nucleotide substitutions was merely a chance event as these samples were originally sequenced because of the large deletions that were detected with PTT. This could indicate that the actual frequency of point mutations in LOH11CR2A could be even higher, suggesting a role for this gene in early onset breast cancer.
The absence of mutations in CHK1 is consistent with previous studies which have failed to identify alterations in consecutive cases of human carcinomas (Haruki et al., 2000) . So far, mutational events have been found only in patients with endometrial and colorectal cancer which had been selected based on the occurrence of microsatellite instability (MSI) in their tumour tissue (Bertoni et al., 1999) . CHK1 contains several stretches of repetitive DNA, the longest one consisting of nine subsequent adenines, and it was at this site that Bertoni et al. (1999) found deletions or insertions in 1/10 colorectal and 2/7 endometrial cancers. In the present study population, we did not ®nd deletions or insertions aecting the region, but considering the low frequency of MSI cases normally found in breast cancer (reviewed by Siah et al., 2000) this was hardly unexpected. Despite its central role in DNA damage repair and checkpoint control, CHK1 does not seem to be a mutational target in carcinogenesis. Intriguingly, Bell et al. (1999) reported mutations of CHK2, a homologue to CHK1 that acts through similar mechanisms in the G2/M checkpoint, in patients with Li-Fraumeni syndrome, which are at high risk of various cancers, including breast cancer. It remains to be seen whether CHK1 will be ruled out as a target for inactivation in tumourigenesis, or if further studies will reveal epigenetic changes such as hypermethylation of the promoter region as the predominant mechanism of inactivation.
Of the four genes analysed in the present study, no one shows a mutation frequency high enough to solely bear the responsibility for the extensive LOH in the area. Based on mutation frequency, the gene most strongly implicated in this subset of breast cancers appears to be PIG8. LOH11CR2A and PPP2R1B also show evidence for involvement but our data do not provide support for an implication of the CHK1 gene. Naturally, the designation of a gene as a tumour suppressor based only on a low to moderate frequency of mutation must remain tentative until further evidence can substantiate its tumour suppressive function. Nonetheless, the present report represents the ®rst indication that PIG8 may be one, and perhaps even the most important, of the tumour suppressor genes at 11q23 ± q24.
Materials and methods

Tumour specimen, RNA and DNA isolation
Specimens from 41 primary breast tumours were collected at the University Hospital, LinkoÈ ping, Sweden. The series of samples included all women, diagnosed during 1996 ± 1999, under the age of 44 years (range 29 ± 43, median 38) where material was available for extraction of RNA and DNA. From the fresh frozen tissue approximately 30 mg was excised for puri®cation of total RNA using the SV Total RNA Isolation System provided by Promega (Madison, WI, USA) following the procedures outlined by the manufacturer. From a subset of samples, 20 mg of the tissue was excised and subjected to a standard proteinase-K/organic extraction protocol in order to isolate DNA for sequencing of exon ± intron borders. Puri®ed DNA and RNA samples were stored at 7708C.
cDNA synthesis
Synthesis of complementary-DNA from total RNA was carried out using the 1st Strand cDNA Synthesis Kit for RT ± PCR by Roche Diagnostics Corp. (Indianapolis, IN,  USA) . Essentially, the reactions were set up according to the guidelines of the manufacturer, although adjustments were made to reach a total volume of 30 ml. The reaction mixture was incubated for 10 min at 258C and then at 428C for 90 min. Finally, enzymes were inactivated at 958C for 10 min.
Protein truncation test, PTT
Primers speci®c for the mRNA sequences of the LOH11-CR2A, CHK1 and PPP2R1B genes were designed using the OLIGO 5.0 software package (National Biosciences Inc., Plymouth, MN, USA). When selecting primers, care was taken so that fragments would not exceed a size of 1.5 kb, making it necessary to divide all three mRNA:s into two overlapping fragments. To eliminate the risk of false negatives in case of alterations in the 3'-end of the ®rst fragment, the size of the overlapping region was designed to equal or exceed 5% of the total fragment length (see Table 2 for details on primers). T7-modi®ed primers were designed according to what has been described by Roest et al. (1993) . PCR-ampli®cations were done in two steps, the ®rst to speci®cally amplify the target fragment, whereas the second step incorporated the modi®ed T7-primer. The Expand High Fidelity PCR System by Roche Diagnostics Corp. (Indianapolis, IN, USA), including an enzyme mix containing Pwo-DNA polymerase with proof-reading activity, was applied for the PCR which was carried out in a total volume of 20 ml including the following reagent concentrations: 16reaction buer, 0.2 mM of dNTP's, 2.5 mM MgCl 2 , 0.3 mM primers, 0.5 u DNA polymerase mix, 0.1 mg/ml BSA, 0.1 ± 1 ng cDNA. Typically, the ®rst round of PCR would consist of a 2 min denaturation step at 958C, followed by 50 cycles of denaturing at 948C for 30 s, annealing at 54 ± 568C (depending on primers used in Table 2) for 30 s and extension at 728C for 1 min. The PCR was concluded with an additional extension step of 7 min at 728C. The second round of PCR was performed similarly but with the T7-modi®ed primer as sense primer and only for 15 cycles. After veri®cation on 1% agarose gels, 2.5 ml of the PCR product was added to a tube containing the reagents for the in vitro transcription and translation, which was performed using the TNT Coupled Reticulocyte Lysate System by Promega (Madison, WI, USA). Reactions were set up essentially as outlined in the manufacturers protocol, although the amount of radio-labelled 35 S-Met (Amersham/Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK) was halved and the total volume of the reaction mixture was scaled down to 20 ml. Samples were incubated at 308C for 90 min after which they were run on denaturing 16.5% TRIS-tricin gels (BioRad Laboratories, Hercules, CA, USA) for 1 h 25 min at 20 W. The gels were then dried and exposed on KODAK BioMax MS X-ray-®lm (Eastman Kodak Company, Rochester, NY, USA) for typically 72 h or, for easier handling, ®rst transferred to a PDF-membrane through Western blotting at 35 W for 1 h after which the dried membrane was exposed on the ®lm as above. Samples exhibiting mobility shifts on the gels were considered as positive for sequence alterations and were subjected to DNA sequencing. To exclude false positives, cDNA-synthesis and PTT-analysis was repeated in samples showing alterations.
Single-strand conformational polymorphism, SSCP
The OLIGO 5.0 software was again employed in the design of ®ve sets of outer and inner primer pairs, dividing the PIG8 mRNA sequence into ®ve overlapping fragments of sizes ranging between 250 and 320 bp (Table 2) . PCR conditions were identical to those described previously (Gentile et al., 1999a) , except for the annealing temperatures which were optimized for each set of primers (Table 2) . Amplicons were con®rmed on 2% agarose gels after which the samples were labelled with [a- 33 P]-dATP (Amersham/Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK) through 18 cycles of PCR and run on 16MDE-gels (BioWhitaker Molecular Application, Rockland, ME, USA) in 0.56TBE buer at 3 W overnight. After drying, the gels were autoradiographed on Kodak BioMax MS X-ray ®lm for typically between 24 ± 72 h at 7708C utilizing TransScreen LE intensifying screens. Samples with mobility shifts were considered to be indicative of sequence alterations, shifted bands were therefore excized from the gels to be veri®ed through DNA sequencing. To exclude artefacts inherent to the methods applied, samples with con®rmed alterations were subjected to new cDNA synthesis, PCR-ampli®cation and SSCP analysis.
DNA sequencing
Samples showing mobility shifts with SSCP or PTT were selected for direct DNA sequencing. Excised bands from SSCP-gels ®rst had to be re-ampli®ed in a nested-PCR under similar conditions to those above, the dierence being a slight increase in annealing temperature, typically 28C, and adjusting the number of cycles to 25 ± 35. Primers from reampli®ed or PTT samples were removed from the PCR The forward primer of each inner primer set was modi®ed as to include the T7-promoter sequence followed by a initiation of translation signal: 5'-GGATCCTAATACGACTCACTATAGGAACAGACCACCATG-3'; b
The position is given in respect to the ®rst nucleotide in the coding sequence, to which number 1 has been designated products using the Wizard Puri®cation System (Promega, Madison, WI, USA) after which the samples were labelled with the Thermo Sequenase Radio Labelled Terminator Sequencing kit (Amersham/Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK) as described previously (Gentile et al., 1999a) . Sequencing primers were also designed in order to analyse intron/exon boundaries for exon 3 of the CHK1 gene. The sequencing reaction was performed using the above mentioned kit, without prior PCR-ampli®ca-tion.
